In the Phase IIb trial, the drug was still benefiting patients after 58 weeks of treatment.

MRNA technology has saved millions of lives through the swift rollout of COVID-19 vaccines from the likes of Moderna and Pfizer. Now, I-Mab wants to replicate that success on a quest to treat cancer.

I-Mab (NASDAQ:IMAB) said an arbitration tribunal awarded no damages to Tracon Pharmaceuticals (NASDAQ:TCON) related to a collaboration agreement but the company would have to pay part of Tracon's ...

AbbVie recently terminated its license and collaboration agreement with I-Mab over its CD47 antibody compounds and products. AbbVie made the decision to end the agreement with the Shanghai-based ...

I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over ...

Having first emerged as therapeutics in the 1980s, monoclonal antibodies (mAbs) are the predominant class of recombinant biologic drugs in development. While intravenous (IV) infusion is a frequently ...

ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...

I-Mab announced positive results from a Phase 1b study of its bispecific antibody, givastomig, which targets Claudin 18.2 and 4-1BB for treating Claudin 18.2-positive gastric cancers. The study, ...

ROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...